Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,507
  • Shares Outstanding, K 53,228
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,210 K
  • 60-Month Beta 1.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/11/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3230 +94.89%
on 03/16/20
0.8100 -22.28%
on 03/19/20
-0.0105 (-1.64%)
since 02/27/20
3-Month
0.3230 +94.89%
on 03/16/20
1.2200 -48.40%
on 02/05/20
-0.3464 (-35.50%)
since 12/27/19
52-Week
0.3230 +94.89%
on 03/16/20
3.1500 -80.02%
on 04/22/19
-0.2005 (-24.16%)
since 03/27/19

Most Recent Stories

More News
Moleculin to Present at the Life Sciences Investor Forum

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.6295 (+1.53%)
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, announces it has entered into a development agreement (the "Agreement") with CNS Pharmaceuticals,...

WBIO.CN : 0.740 (-2.63%)
CNSP : 2.12 (-11.30%)
MBRX : 0.6295 (+1.53%)
Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.6295 (+1.53%)
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial...

MBRX : 0.6295 (+1.53%)
WPD PHARMACEUTICALS' WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, announces, that its license partner Moleculin Biotech, Inc. (Nasdaq: MBRX)("Moleculin"),...

WBIO.CN : 0.740 (-2.63%)
MBRX : 0.6295 (+1.53%)
Coronavirus Puts Drug Repurposing on the Fast Track

Chinese and western biotech companies have been gearing up to repurpose existing drugs, approved in the West for other viruses, as treatments for the coronavirus outbreak originating in Wuhan. Chinese...

MBRX : 0.6295 (+1.53%)
MRNA : 30.05 (+7.55%)
AYTU : 1.8200 (+13.75%)
INO : 8.32 (+16.36%)
NNVC : 5.68 (+1.97%)
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that...

MBRX : 0.6295 (+1.53%)
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that...

MBRX : 0.6295 (+1.53%)
Moleculin Issues Video Shareholder Letter

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today issued...

MBRX : 0.6295 (+1.53%)
WPD Pharmaceuticals' Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute Myeloid...

WBIO.CN : 0.740 (-2.63%)
MBRX : 0.6295 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 0.6776
1st Resistance Point 0.6535
Last Price 0.6295
1st Support Level 0.5977
2nd Support Level 0.5660

See More

52-Week High 3.1500
Fibonacci 61.8% 2.0701
Fibonacci 50% 1.7365
Fibonacci 38.2% 1.4029
Last Price 0.6295
52-Week Low 0.3230

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar